MetaCap

Allogene Therapeutics Insider Trades

NASDAQ: ALLOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.46+0.06 (+4.29%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
0 · $0
Sales
15 · $666.28K
Shares bought / sold
0 / 355.26K
Net activity
Net selling $666,282

Allogene Therapeutics insider activity

Over the last 12 months, Allogene Therapeutics insiders reported 17 transactions on SEC Form 4: 0 open-market purchases and 15 sales. Insiders bought $0 and sold $666,282 worth of stock, for net insider selling of $666,282. The largest seller was Chang David D, with $289,459 in reported sales.

The most recent filing shows Douglas Earl Martin (SVP, General Counsel) selling 29,697 shares at $2.12 on Aug 21, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put ALLO's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

ALLO insider transactions

Allogene Therapeutics insider transactions
DateInsiderTypeSharesValueFiling
Aug 21, 2026Douglas Earl MartinSVP, General CounselSale29,697$62.96KForm 4
Jun 18, 2026Kazam Joshua ADirectorOption exercise47,700—Form 4
Apr 21, 2026Yoshiyama AnnieSVP, FinanceSale9,586$22.14KForm 4
Mar 31, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerSale2,867$7.17KForm 4
Mar 16, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerSale4,835$11.94KForm 4
Mar 16, 2026Chang David DPresident and CEOSale47,763$117.97KForm 4
Mar 2, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerSale7,132$18.54KForm 4
Feb 2, 2026Roberts ZacharyEVP of R&DSale35,700$63.19KForm 4
Feb 2, 2026Douglas Earl MartinSVP, General CounselSale22,900$40.30KForm 4
Feb 2, 2026Parker Geoffrey M.CHIEF FINANCIAL OFFICERSale24,001$42.24KForm 4
Feb 2, 2026Chang David DPresident and CEOSale95,269$171.48KForm 4
Feb 2, 2026Yoshiyama AnnieSVP, FinanceSale4,167$7.17KForm 4
Feb 2, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerSale7,549$13.06KForm 4
Jan 21, 2026Roberts ZacharyEVP of R&DSale26,269$40.98KForm 4
Dec 18, 2025Kazam Joshua ADirectorOption exercise47,700—Form 4
Nov 17, 2025Beneski Benjamin MachinasSVP, Chief Technical OfficerSale786$958.92Form 4
Oct 21, 2025Parker Geoffrey M.CHIEF FINANCIAL OFFICERSale36,744$46.17KForm 4
Jun 10, 2025MESSEMER DEBORAH M.DirectorSale36,885$52.38KForm 4
Apr 21, 2025Yoshiyama AnnieSVP, FinanceSale9,601$13.54KForm 4
Mar 14, 2025Chang David DPresident and CEOSale46,668$91.47KForm 4
Mar 14, 2025Beneski Benjamin MachinasSVP, Chief Technical OfficerSale5,488$10.84KForm 4
Mar 1, 2025Beneski Benjamin MachinasSVP, Chief Technical OfficerAward31,755—Form 4
Feb 18, 2025MESSEMER DEBORAH M.DirectorSale13,313$32.35KForm 4
Feb 3, 2025Parker Geoffrey M.CHIEF FINANCIAL OFFICERSale4,361$7.54KForm 4
Feb 3, 2025Douglas Earl MartinSVP, General CounselSale6,404$10.95KForm 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related